Grass Pollen Allergy
Conditions
Keywords
grass pollen allergy, immunotherapy, recombinant vaccine
Brief summary
The study will evaluate the dose response of immunotherapy against grass pollen allergy using the recombinant grass pollen vaccine BM32. Efficacy will be analyzed by: * skin prick testing * grass pollen inhalation challenge * antibody responses. In addition, the safety of subcutaneous application of BM32 will be evaluated.
Interventions
BIOLOGICALBM32
Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
BIOLOGICALPlacebo
Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
Sponsors
Biomay AG
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* History of seasonal allergic rhinitis from grass pollen * Normal electrocardiogram * Moderate to severe response to approx. 1500 grass pollen grains/m3 after 2 hrs of exposure in challenge chamber * Positive skin prick test for grass pollen at or within 12 months preceding screening visit * Positive RAST (class 2 or higher) for timothy grass pollen and to rPhl p 1 + rPhl p 5 at or within 12 months preceding screening visit
Exclusion criteria
* Pregnant or lactating females * Females with childbearing potential not using medically acceptable birth control * Structural nasal abnormalities, nasal polyposis, history of frequent nosebleeds, recent nasal surgery or ongoing upper respiratory tract infection * Any respiratory disease other than mild asthma controlled with occasional short acting beta agonists and normal lung function * Current or recent participation in another clinical trial * SIT for grass pollen allergy in the last two years prior to study * Past or present disease, which may affect outcome of the trial, judged by investigator * Autoimmune diseases, immune defects including immunosuppression, immune- complex immunopathies * Suspected hypersensitivity to any ingredients of study medication * Use of prohibited medication prior to screening and throughout study * depot corticosteroids (12 weeks) * oral corticosteroids (8 weeks) * inhaled corticosteroids (4 weeks) * Allergic symptoms at the time of screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Minimum effective dose for reduction of total nasal symptom score (TNSS) after inhalation challenge with grass pollen | Baseline and 14 weeks | Difference in the total Nasal Symptom Score (TNSS) between spending 6 hrs in the Vienna Challenge Chamber (VCC) at screening and spending 6 hrs in the VCC four weeks after the last subcutaneous injection of BM32. |
Secondary
| Measure | Time frame |
|---|---|
| Minimum effective dose for reduction of Global symptom Score upon inhalation challenge with grass pollen | Baseline and 4 weeks after final s.c. injection |
| Minimum effective dose for reduction of nasal airflow resistance after inhalation challenge with grass pollen | Baseline and 14 weeks |
| Minimum effective dose to reduce skin reaction to grass pollen allergen upon skin prick testing | Baseline and 14 weeks |
| Difference in FEV1 and FEV/FVC between screening and completion of vaccination | Baseline and 14 weeks |
| Frequency of local reactions to treatment | average of 8 weeks from 1st to last injection |
| Minimum Effective dose for reduction of Total Non-Nasal Symptom Score (TNNSS) following inhalation challenge with grass pollen | Baseline and 14 weeks |
| Change in allergy specific IgE | Baseline and average of 12 weeks after randomization |
| Frequency of systemic reactions to treatment | average of 8 weeks from 1st to last injection |
| Severity of local reactions to treatment | Average of 8 weeks from 1st to last injection |
| Severity of systemic reactions to treatment | Average of 8 weeks from 1st to last injection |
| Frequency of adverse events | average of 14 weeks from 1st injection |
| Change in allergy specific total IgG | Baseline and average of 12 weeks after randomization |
Countries
Austria
Outcome results
None listed